Email Us
Call Us
Gamma delta T cells occupy a position between adaptive and innate immunity. They recognize stress-associated molecules and phosphoantigens rather than peptide presented by major histocompatibility complex, which means recognition does not depend on HLA matching between donor and recipient. That single property is what makes the approach attractive as an allogeneic cell therapy: an off-the-shelf product can be administered without the HLA matching that constrains conventional T-cell therapy, and without the graft-versus-host disease risk that donor alpha beta T cells carry.
Altogen Labs conducts preclinical evaluation of gamma delta T-cell products across disseminated and solid tumor models, with antitumor activity, persistence, and trafficking assessed together. To discuss a study design, request a quote.
Recognition and model selection
Because gamma delta recognition proceeds through stress ligands and phosphoantigen sensing rather than through a tumor-specific antigen, the relevant model characteristic is the stress ligand profile of the tumor line rather than expression of a defined target. Two lines of the same histology can differ substantially in susceptibility, and selecting a model without regard to that profile risks a null result that reflects the substrate rather than the product.
Where the product or a combination partner acts by increasing phosphoantigen accumulation, the study design should establish the contribution of that mechanism directly, with and without the sensitizing agent, rather than reporting the combination effect alone.
Cytokine support and persistence
As with other human lymphocyte products, survival and expansion of transferred human gamma delta T cells in a murine host depend on cytokine support that murine cytokines do not adequately provide. Persistence measured without that support characterizes the model rather than the product. Host selection, supplementation, or engineered cytokine independence is settled at design stage and reported alongside persistence data, so that a short persistence result is interpretable.
Endpoints
Antitumor activity is assessed by tumor volume in solid models and by longitudinal imaging in disseminated models. Persistence, phenotype, and subset composition of the transferred product are quantified by flow cytometry in blood and tissue. Immunohistochemistry establishes whether transferred cells entered the tumor mass in solid models, and cytokine analysis characterizes the response profile.
Applied examples
Ligand-dependent susceptibility. A gamma delta product is evaluated against tumor lines differing in stress ligand expression, relating antitumor activity to ligand status rather than to tumor histology.
Sensitization combination. A product is administered with and without an agent that increases phosphoantigen accumulation, quantifying the contribution of sensitization to the overall effect.
Solid tumor trafficking. Transferred cells are quantified in tumor, blood, and spleen at defined timepoints, distinguishing limited killing from limited trafficking as the explanation for modest activity in a solid model.
Interpretive limits and service boundary
Gamma delta T-cell biology differs substantially between human and mouse, and murine hosts do not reproduce the human receptor repertoire or its ligand interactions. Results establish activity within the model system used, and the characteristics of that system are stated in the report rather than assumed. Where allogeneic tolerability is part of the rationale for the approach, that property cannot be demonstrated in a host lacking a competing human immune compartment, and the study reports what it tested rather than implying more.
Altogen Labs evaluates cell products supplied by the client. Manufacture of gamma delta T-cell or other cell therapy products is not offered. All procedures are conducted under active IACUC protocols. GLP standards are applied where a study is formally designated as GLP.
Send product type, tumor indication, and mechanism of interest, or request a quote.